OXFORD BIOMEDICA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 327.5 GBX | +1.71% |
|
+2.03% | +48.41% |
| 05-09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
| 05-09 | Molten Ventures wins UK MoD supply contract | AN |
Presenter SpeechFrank Mathias (Executives)Good afternoon, everyone. And obviously, good mornin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Calendar
2024-06-23
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.22
GBP
Average target price
4.304
GBP
Spread / Average Target
+33.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.41% | 408M | |
| +7.52% | 113B | |
| +11.38% | 106B | |
| +1.43% | 22.27B | |
| -12.64% | 22.22B | |
| -5.10% | 19.43B | |
| -37.85% | 17.87B | |
| -8.58% | 17.24B | |
| +7.77% | 14.29B | |
| +37.41% | 12.52B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Transcript : Oxford Biomedica plc, Q4 2023 Earnings Call, Apr 29, 2024